Entero Therapeutics (NASDAQ:ENTO) Rating Increased to Hold at Wall Street Zen

Entero Therapeutics (NASDAQ:ENTO) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Friday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Entero Therapeutics in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Entero Therapeutics Trading Up 0.2%

Shares of Entero Therapeutics stock opened at $4.35 on Friday. The stock has a 50 day moving average of $2.77 and a 200 day moving average of $1.83. Entero Therapeutics has a fifty-two week low of $0.97 and a fifty-two week high of $5.47.

Entero Therapeutics (NASDAQ:ENTO) last posted its earnings results on Thursday, August 14th. The company reported ($0.42) EPS for the quarter.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.